Policy Developments - The National Healthcare Security Administration (NHSA) has initiated the 11th batch of centralized procurement, optimizing the selection rules by no longer solely relying on the lowest bid as a reference. Companies with the lowest bids must now justify the reasonableness of their pricing and ensure it does not fall below cost [2] Drug and Medical Device Approvals - Senxuan Pharmaceutical's subsidiary has received approval for the market launch of Ritonavir raw materials, an antiviral drug primarily used for treating AIDS and also utilized during the COVID-19 pandemic [4] - Hengrui Medicine's subsidiary has received a clinical trial approval notice for the injectable HRS8179 drug, aimed at preventing severe brain edema after large-scale cerebral infarction. The project has seen a cumulative R&D investment of approximately 47.4 million yuan [5] Financial Reports - Sino Medical anticipates a 296.54% year-on-year increase in net profit for the first half of 2025, with expected revenue of 240 million yuan, reflecting a 12.53% growth [7] - WuXi Biologics forecasts a revenue growth of about 16% for the first half of the year, with profits expected to increase by approximately 54% and 56% for the company and its equity shareholders, respectively [8] Capital Markets - Lianhuan Pharmaceutical plans to issue up to 500 million yuan in technology innovation bonds to enhance R&D capabilities and optimize its debt structure. The bonds will be publicly issued with a term of no more than three years [10] Industry Developments - The NHSA has reported that over 100 drug varieties have applied to be included in the commercial health insurance innovative drug directory, which aims to incorporate high-value innovative drugs that cannot yet be included in the basic medical insurance directory [12] - As of the end of 2024, the cumulative recovery of medical insurance funds has reached 104.5 billion yuan, with a total balance of 3.86 trillion yuan in the insurance fund [14]